Hawaii Chapter - NHF
Phone 808-284-7417

Our Mission

The National Hemophilia Foundation (NHF) Hawaii Chapter is dedicated to finding cures for inheritable blood disorders and addressing and preventing complications of these disorders through research, education, and advocacy enabling people and families to thrive.  

News Articles

On November 22, the U.S. Food and Drug Administration approved Hemgenix (etranacogene dezaparvovec), an adeno-associated virus (AAV) vector-based gene therapy. It is approved for the treatment of adults with hemophilia B who currently use factor IX (FIX) prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.

Historically, many residential substance use disorder (SUD) facilities have denied admittance to individuals with bleeding disorders – the basis of these denials are most often the use of self-administered, intravenous medications such a as factor replacement therapies. The lack of access to residential addiction treatment facilities, can have very serious, even fatal outcomes for bleeding disorder (BD) patients in acute need of help with their addiction.

MEDIA CONTACT: 

Ilana Ostrin 

212-328-3769 
iostrin@hemophilia.org 

 

View All

Resource Links

Hawaii Chapter - NHF
75-5660 Kopiko Street, Suite C7 #294
Kailua-Kona, HI 96740
Phone 808-284-7417

© Hawaii Chapter Hemophilia Foundation 2022

Crafted by Firespring